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Six normal male volunteers received 0.5rag label doses of digoxin as (a) a bolus intravenous 
injection over 2 rain, (b) a constant rate intravenous infusion over I hr, (c) a constant rate 
intravenous infusion over 3 hr, and (d) a solution in 5% dextrose given orally. Plasma 
concentrations of digoxin were measured by radioimmunoassay for a 4 day period and urinary 
excretion for a 6 day period after the single doses. The mean (coefficient of variation) total areas 
under the plasma concentration-time curves per 0.5 mg of digoxin were (a) 35.55 (14.8%), (b) 
30.20 (27. 7% ), (c) 25.80 (35.5%), and (d) 15.47 (49.9%); the means differed significantly 
(0. 01 > p > O. 005). The mean (coefficient of variation) total amounts excreted in the urine as a 
fraction of the dose were (a) 0.689 (6.31%), (b) 0.517(20.4%), (c) 0.588 (16.8%), and (d) 0.374 
(23.4%); the'means differed significantly (p < 0.001). Both the total clearance and the nonrenal 
clearance of digoxin differed significantly with the method of intravenous administration. The 
slower the rate of input of digoxin to the body, the greater were both the total clearance and the 
nonrenal clearance of the drug, which strongly suggests nonlinear pharmacokinetics. 
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INTRODUCTION 
The human study discussed in this article was designed to elucidate 
certain discrepancies in digoxin pharmacokinetics that were reported by 
other investigators. Greenblatt et al. (1) administered doses of 0.75 mg of 
digoxin by both rapid intravenous injection (over a 2 to 3 rain period) and in 
250 ml of 5% dextrose in water over a 1 hr period by means of a constant 
rate infusion pump to a panel of eight healthy males. They reported that (a) 
the mean 6 day cumulative urinary excretion of digoxin after rapid injection, 
0.52 mg (69% of the dose), was significantly (p < 0.001) lower than that 
after 1 hr infusion, 0.57 (76%); (b) between subject variability in cumulative 
urinary excretion after rapid intravenous injection (coefficient of variation = 
7.5% of the mean) was significantly (p <0.01) greater than after l h r  
infusion (coefficient of variation = 2.2% of the mean); and (c) mean areas 
0-8 hr under the serum concentration-time curves were not significantly 
different for the rapid injection and 1 hr infusion. 
Marcus et al. (2) administered 0.4 mg doses of digoxin to five normal 
volunteers both as a constant rate infusion over 1 hr and as an infusion over 
3 hr with 0.1 mg of the digoxin being infused during the first hour, 0.2 mg 
being infused during the second hour, and 0.1 mg being infused during the 
third hour. They reported: "The most striking finding in our study was that 
the 6 day urinary excretion of digoxin after a 3 hr infusion was 21% more 
than after the same dose of drug given during the 1 hr infusion." 
Linear pharmacokinetic theory indicates that the total area under the 
serum or plasma concentration-time curve, AUC 0-~,  and the total amount 
excreted in the urine, A e  ~, after single doses of a drug should be the same 
whether the drug is administered as a bolus injection, as a 1 hr infusion, or as 
a 3 hr infusion. This was the hypothesis tested by the study we report on 
herein. 
E X P E R I M E N T A L  
H u m a n  Study 
Six young adult male volunteers with no known disease who weighed 
between 66 and 96 kg were selected. Normal complete physical examina- 
tion, routine blood and urinalysis, normal values for kidney and liver 
function tests, and normal resting 12 lead electrocardiograms were neces- 
sary for entry into the study. Informed consent was obtained from each 
subject. 
A recent drug history was taken for each prospective subject. All 
subjects participating in the study received no barbiturates or other enzyme- 
inducing agents for a period of 30 days preceding initiation of the study and 
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none concurrent  with it. They received no other medication or alceholic 
beverages for a period of 7 days before initiation of the study and none 
during the study. 
At  8:30 p.m. each night before dosing with digoxin, the subjects were 
admitted to the Clinical Research Center  of University Hospital, The 
University of Michigan. They ate a snack at 9:30 p.m. that night, then fasted 
from that time until 4 hr after dosing with digoxin the next day. On the days 
of dosing, they ate standard lunches and suppers, which combined provided 
1240 calories consisting of 22% protein, 17% fat, and 61% carbohydrate.  
Subjects drank lemonade and received neither tea or coffee on the days of 
dosing. Subjects were supine during the days they received digoxin. 
Treatments  were as follows. A: 2cc of digoxin injection containing a 
label dose of 0.5 mg of digoxin was given. The solutions used for treatments 
B, C, and D were prepared under sterile conditions by adding the contents of 
the same lot of digoxin injection to sterile 5% dextrose in water. B: a label 
dose of 0 .5mg of digoxin in 240ml  of 5% dextrose was infused 
intravenously at a constant rate over a 1 hr period. C: a label dose of 0.5 mg 
digoxin in 360 ml of 5% dextrose was infused intravenously at a constant 
rate over a 3 hr period. D: a label dose of 0.5 mg digoxin in 240 ml of 5% 
dextrose was administered orally; then the container was rinsed and the 
contents swallowed. 
The treatments were administered to the subjects as indicated by the 
study plan shown in Table I. There  were three intravenous treatments; 
hence, there were six possible treatment sequences for these, and each 
subject received a different iv t reatment  sequence in crossover fashion. For 
the fourth phase, all received the oral treatment.  Treatments  were separated 
by two week periods. 
Ten milliliters of whole blood were taken at zero time (just before 
dosing) and at 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 24, 48, 72, and 96 hr 
after t reatment A; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 25, 49, 73, and 97 hr 
after t reatment B; 1, 2, 3, 3.25, 3.5, 3.75, 4, 5, 6, 7, 11, 27, 51, 75, and 99 hr 
Table I. Treatment Schedule in Human Study 
Treatment in indicated phase 
Subject I II IiI IV 
1 A B C D 
2 B C A D 
3 C A B D 
4 A C B D 
5 B A C D 
6 C B A D 
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after treatment C; and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 24, 48, 72, and 96 hr 
after treatment D. Prior experience in performing digoxin bioavailability 
studies had indicated that these sampling times defined well the concen- 
tration-time curves after the different methods of administration. Blood was 
drawn in vacutainers containing sodium heparin. Plasma, obtained by 
centrifugation shortly after withdrawal of the blood, was quick-frozen and 
stored at -20~ until just before assay. Urine was collected in 12 hr periods 
for 6 days after dosing. After measurement of the volume and adequate 
mixing, a 30 ml aliquot of each urine was frozen and maintained at -20~ 
until just prior to assay. 
Assay of Plasma and Urine Samples 
Plasma and urine samples were assayed by the radioimmunoassay 
method of Wagner et  al. (3). This assay measures digoxin down to 0.05 ng 
digoxin per ml of plasma. Each sample was assayed independently by two 
different analysts, and the results were averaged. Calibration data were 
obtained by each analyst on each day unknowns were assayed. For plasma 
and urine, these standards contained 0, 0.05, 0.1, 0.5, 1, 2, and 5 ng digoxin 
per milliliter. For all days, the 0.05 ng/ml plasma was distinguished from the 
0 sample by having a lower percent bound value. The plasma assay utilized 
0.5 ml of plasma, while the urine assay employed only 10 ;xl of urine and 
100 p~l of digoxin-free plasma. For calibration purposes, the normalized 
fraction of digoxin bound, F, is given by 
F = B ( x ) / B ( O )  (1) 
where B (x) is the percent digoxin bound at the concentration C and B (0) is 
the percent digoxin bound in the absence of digoxin. Each day of assay, each 
analyst's binding data for the above standards gave a straight line by the 
method of least squares based on the logarithmic logistic equation 
In [(1 - F ) / F ]  = In O +S  In C (2) 
where In Q is the intercept (corresponding to C = 1), and S is the slope when 
the lefthand side of Eq. (2) was plotted against In C. Correlation coefficients 
for individual standard curves varied from 0.991 to 1.00 with the vast 
majority being 0.999. Concentrations of unknowns were inversely esti- 
mated by rearranging Eq. (2) to Eq. (3): 
C = e {ln~l-F/F~-ln~ (3) 
On a given day, each analyst analyzed all the plasma samples or all the urine 
samples of one subject. The values of In O and S obtained from the 
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calibration standards run that same day by the same analyst were then 
substituted into Eq. (3) to calculate digoxin concentrations of the unknown 
samples. Errors involved in this assay have been discussed elsewhere (3). 
Samples containing >5 ng digoxin/ml were diluted. 
Multiple radioimmunoassays were performed on the ampules of the 
same lot used for bolus injections and on the three solutions used for 
treatments B, C, and D to obtain the doses by assay, which were 447,479, 
492, and 547 ~g for treatments A, B, C and D, respectively. The solution 
remaining in the infusion tubing after treatments B and C was blown out, the 
tubing was rinsed, and this mixture was assayed for each subject. Then this 
amount was subtracted from the 479 and 492 ~g above to give the actual 
dose per subject. Usually such care is not taken, but the differences of label 
from actual doses are large enough that appreciable error would be intro- 
duced if they are not accounted for. 
R E S U L T S  A N D  E V A L U A T I O N  
Table II lists the average digoxin plasma concentrations and the cor- 
responding coefficients of variation. Table IiI lists the average urinary 
excretion rates and the average amounts excreted in the urine in 6 days as 
well as the mean 0 to ~ values. Table IV gives the mean values and the 
coefficients of variation of pharmacokinetic parameters, which were esti- 
mated by the methods given in the Appendix. 
Since the study design (Table I) involved a crossover design utilizing all 
six possible treatment sequences for the three methods of intravenous 
administration, an analysis of variance for crossover design was performed 
for each set of such data comprising 18 numbers. The underlined mean 
values in each row of Table IV indicate that the differences among the means 
were significant when analyzed by this method. The results of these analyses 
are summarized in Table V. The fourth column of Table V indicates that in 
no case was the among periods mean square significant. For several of the 
parameters, the oral data were then added to the intravenous data (total of 
24 numbers per set), and a two factor analysis of variance was performed. 
Results are listed in Table VI. 
Table VII lists the mean apparent systemic bioavailabilities estimated 
by three different methods involving different assumptions. The equations 
used are given as Eq. (A1) through (A17) in the Appendix. Results of two 
factor analyses of variance of these data are given in the last three rows of 
Table VI. It should be noted that since both total clearance and nonrenal 
clearance of digoxin changed significantly with the method of intravenous 
administration, none of the three methods of estimating systemic availability 
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Table IlL Average Urinary Excretion Rate and Amounts Excreted in Urine with Their 
Coefficients of Variation 
Urinary excretion rate (ixg/day) 
Bolus iv 1 hr inf. 3 hr inf. Oral solution 
Rate CV Rate CV Rate CV Rate CV 
Day (ixg/day) (%) (Ixg/day) (%) (ixg/day) (%) (ixg/day) (%) 
1 182 15.1 134 43.6 159 11.9 94.2 31.5 
2 49.2 20.6 42.0 22.6 55.6 56.0 46.0 46.0 
3 34.1 19.2 29.4 28.1 37.5 43.2 28.1 28.5 
4 17.9 45.2 17.9 34.2 16.1 36.2 14.1 28.8 
5 10.5 28.0 8.29 32.5 8.64 57.5 8.02 58.7 
6 8.48 71.5 7.86 50.0 6.23 43.9 5.17 39.4 
0-6 ~ 302 6.52 236 22.5 283 16.9 198 22.9 
0-m b 308 6.33 244 19.9 287 16.9 204 23.3 
~Average amount of digoxin excreted in urine in 6 days (~g). 
bEstimated average amount of digoxin excreted in urine in infinite time (l~g). 
Considerable effort was expended in estimating by different methods 
several of the pharmacokinet ic  parameters  and comparing the results statis- 
tically to ensure that observed differences were not artifacts. Areas  under 
the plasma concentrat ion-t ime curves, A U C  O-T,  to the last sampling time 
T (96 hr postadministrat ion for t reatments  A and D and 96 hr postinfusion 
for t reatments  B and C) were obtained by applying the trapezoidal rule up to 
the peak concentration, then the logarithmic trapezoidal rule f rom the peak  
concentration onward. Details are given in the Appendix.  These areas were 
then corrected for the dose by assay symbolized by D. The means and 
coefficients of variations of these areas are given in the first row of Table IV. 
The estimated total areas under  the concentrat ion-t ime curves, A U C  0-co, 
were est imated by three different methods as described in the Appendix.  
The mean dose-corrected total areas per  0.5 mg of digoxin are shown in the 
third row of Table IV, and these areas were calculated by application of Eq. 
(A3) of the Appendix.  These areas, A U C  0-oe, est imated by different 
methods,  agreed very well with each other. The  mean of 24 areas (6 
subjects x 4 treatments)  obtained by application of Eq. (A1) through (A3) of 
the Appendix,  namely, 25.61 (ng/ml) hr, did not differ significantly f rom the 
mean area of 25.76 (ng/ml) hr obtained by polyexponential  fitting followed 
by integration, as indicated by Eq. (A7) through (A9) in the Appendix  
(paired t = 0 . 4 0 ,  p > 0 . 2 5 ) .  Also, the mean area of 27.85 (ng/ml) hr, 
obtained by applying Eq. (A 1) through (A3), did not differ significantly f rom 
the mean area of 28.29 (ng/ml) hr obtained by application of Eq. (A4) for 22 
sets of data, where such a comparison was feasible (paired t = 1.89, 0.10 > 
p > 0.05). 
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Table IV. Summary of Average Parameter Values and Coefficients of Variation 
Mean Parameter Value with Coefficient of Vari- 
ation 
Symbol and Bolus 1 hr 3 hr Oral 
Parameter dimensions iv inf. inf. solution 
32.85 a 26.85 23.75 14.50 
( ~  (21.0) (35.1) (47.2) 
0.675 0.500 0.579 0.361 
in urine in 6 days (6.53) (22.9) (17.0) (23.0) 
Dose-corrected total [AUC] ['0.5] 35.55 30.20 25.80 15.47 
area per 0.5 mg digoxin / 1 / / k  0-oo J D-A (14.8) (27.7) (35.5) (49.9) 
ml J 
Fraction of dose excreted A~/D 0.689 0.517 0.588 0.374 
in urine from 0 to m (6.31) (20.4) (16.8) (23.4) 
Total clearance CIt 23_.99 30__00 366 675 
(ml/min) (16.2) (35.7) (41.8) (51.5) 
Renal clearance C1, 164 157 215 240 
(ml/min) (10.8) (49.4) (42.3) (50.3) 
Nonrenal clearance Clnr 7_55 14.__33 15__11 435 
(ml/min) (30.5) (31.9) (54.3) (58.8) 
Nonrenal clearance as Clnr/Clt 0.309 0.483 0.413 0.627 
fraction of total (14.5) (21.6) (24.0) (13.9) 
clearance 
Elimination rate /3 0.0252 0.0263 0.0313 0.0340 
constant ihr -1) (24.1) (33.1) (27.9) (25.1) 
Elimination halflife 0.693//3 28.6 28.2 23.5 21.6 
(hr) (19.2) (23.9) (25.5) (26.0) 
Volume of distribution V~ 580 690 716 c 
(liters) (12.9) (19.7) (30.9) 
Dose-corrected area per [AUC] [0.5] 
0.5 mg of digoxin I_ 0-T .1 [ D J 
Fraction of dose excreted A~/D 
~Mean b parameter value of 6 subjects; see text for meaning of underlining. 
Bracketed number is the coefficient of variation in percent. 
CShould not be calculated for oral administration. 
I t  shou ld  be  n o t e d  tha t  the  m e t h o d  of e s t ima t ing  the  A U C ' s  for  the  
bo lus  i n t r avenous  t r e a t m e n t  gave  the  mos t  conse rva t ive  va lues  poss ib le .  T h e  
a r ea  u n d e r  the  ini t ia l  pa r t  of the  c o n c e n t r a t i o n - t i m e  curve  was e s t i m a t e d  as 
a r e a  of the  t r i angle  f o r m e d  f rom the  or ig in  (0,0 point ) ,  the  c onc e n t r a t i on  at 
0 .167 hr,  and  at 0 .167 hr. In  e s t ima t ing  A U C s  f rom p o l y e x p o n e n t i a l  f i t t ing 
of the  bo lus  c o n c e n t r a t i o n - t i m e  da ta ,  the  p o l y e x p o n e n t i a l  e q u a t i o n  was 
i n t e g r a t e d  f rom 0.167 hr  to infinity,  t hen  the  a r ea  of the  t r i angle  d i scussed  
a b o v e  was added .  If one  used  the  Co va lue  o b t a i n e d  by  p o l y e x p o n e n t i a l  
f i t t ing in e s t ima t ing  the  a rea ,  much  h igher  A U C  values  were  o b t a i n e d ,  and  
the  d i sc repancy  b e t w e e n  A U C s  fo l lowing  bo lus  in jec t ion  and  the  infus ions  
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Table VII. Apparent Systemic Availabilities 
157 
Average apparent systemic availabilities 
Bolus 1 Hr 3 Hr 
Method Assumption iv InL inf. Oral 
A Constant Cl,, but variable Clr 1.00 0.772 0.807 0.526 
(13.5) a (10.1) (27.2) 
B Proportional change in Cl,,r 1.00 0.753 0.853 0.584 
with change in Clr (22.3) (15.5) (26.8) 
C Constant CIt 1.00 0.845 0.720 0.439 
(23.2) (30.0) (49.2) 
aNumber in parentheses is coefficient of variation (%). 
Apparent  elimination rate constants, /3, were estimated by three 
different methods: one using Eq. (A3), a second using Eq. (A5), and a third 
using Eq. (A3), except that (Ae)i  and (Ae)i+l replaced (AUC)~ and 
(AUC)I+I, respectively. With three/3 values per subject per t reatment  (total 
72 values), a three factor analysis of variance with subjects, treatments, 
methods, and residual as sources of variation was carried out. The mean 
square for methods, 0.44, was not significant (p > 0.25); the mean square for 
treatments, 3.25, was significant (0.05 > p  > 0.025), as well as the mean 
square of 5.17 for subjects ( p < 0 . 0 0 1 ) .  Thus with these data, there was 
evidence that the elimination rate constant increased with decrease in the 
rate of input of digoxin to the body (i.e., bolus iv > 1 hr inf. > 3 hr inf. > oral). 
The three estimates of/3 for each subject in each treatment were averaged, 
then these six values were averaged again to provide the mean/3  values 
shown in the ninth column of Table IV. However,  when the 18 average/3 
values for the three intravenous treatments were analyzed by analysis of 
variance for crossover design, or the 24 average /3 values for all four 
treatments were analyzed by two factor analyses of variance, there were no 
significant differences among the treatment averages (9th row of Tables IV 
and V, and 6th row of Table VI). 
D I S C U S S I O N  
In our study, both the total and nonrenal clearances of digoxin differed 
significantly with the method of administration. The portal vein concen- 
tration-time profiles of digoxin following oral administration of digoxin 
extend beyond 6 hr (4), indicating that oral administration provides a slower 
input rate to the body than a 3 hr infusion. Thus in our study, the slower the 
rate of input of digoxin to the body, the greater were both the total clearance 
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and the nonrenal clearance. This strongly suggests nonlinear pharmaco- 
kinetics, and specifically, some type of saturation phenomenon in the liver. 
The results obtained in our study are the opposite of those reported by 
Greenblatt et al. (1). They reported that 6 day urinary excretion after rapid 
iv injection, 69% of the dose, was significantly (p < 0.001) lower than after 
1 hr infusion, 76%, and variation of excretion was greater after rapid 
injection than after 1 hr infusion. Our data (Table IV) show that 6 day 
urinary excretion after rapid iv injection, 67.5% of the dose, was 
significantly greater than after 1 hr infusion, 50% of the dose, and the 
coefficient of variation, 6.53%, after rapid iv injection was much less than 
the corresponding value of 22.4% following 1 hr infusion. So far as ratios are 
concerned, results obtained in our study agreed with those reported by 
Marcus et al. (2). They reported that 60, 70, and 51% of the dose (ratios of 
1.0, 1.17, and 0.85) were excreted in the urine in 6 days following 1 hr 
infusion, 3 hr infusion and oral solution, respectively; whereas in our study, 
the corresponding values (row 2 of Table IV) were 50, 58, and 36% of the 
dose (ratio 1.0, 1.16 and 0.72) for the same routes of administration, 
respectively. Unfortunately, clearances could not be estimated from either 
the data of Greenblatt et al. (1) or Marcus et al. (2) since they sampled blood 
only over 8 and 6 hr, respectively (5). 
Another type of nonlinearity was reported by Huffman et al. (6). They 
reported that doubling of the digoxin dose given by bolus intravenous 
injection from 0.125 to 0.25 mg doubled the amount of digoxin excreted in 
the urine during a dosage interval at steady state, whereas the area under the 
serum digoxin concentration-time curve at steady state increased by only 
50% for oral administration and only 80% for intravenous administration. 
In linear pharmacokinetics, the amount excreted during a dosage interval at 
steady state is equal to the amount excreted from zero to infinite time after a 
single dose. In the study of Huffman eta l .  (6), the amounts excreted during a 
dosage interval at steady state were measured. In our study and in the study 
of Koup et al. (7), A e  ~176 was estimated. From these urinary excretion data 
reported in the three studies, one can calculate that the average fractions of 
the doses excreted in the urine were 0.401, 0.418, 0.675, and 0.755 for the 
0.125, 0.25, 0.5, and 0.75 mg doses, respectively. Thus this interstudy 
comparison also indicates a type of nonlinearity in digoxin pharmaco- 
kinetics. 
Some other comparisons of our results with those reported by others 
are noteworthy. Lloyd et al. (8) appropriately collected sufficient data and 
evaluated it correctly to allow estimation of total clearance of digoxin. From 
their data (8), one can calculate a mean total clearance of digoxin of 
328 ml/min following administration of 0.4 mg doses infused intravenously 
over 1 hr, which agrees quite well with the mean total clearance of 
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300 ml/min (5th row of Table IV) obtained following the 1 hr infusion in our 
study. Lisalo (9), in a review, summarized urinary excretion of digoxin 
following single intravenous doses where urine was collected from 6 to 10 
days; the percentages were 70.5, 70.1, 80, 76, 57, 68, and 70.8% (average 
70%). Our mean percentage of 67.5% folowing the bolus intravenous 
method (row 2 of Table IV) agrees well. The apparent systemic availability 
of digoxin of 44 to 55% of the oral dose in solution form in our study 
(Table VII) is considerably lower than that reported by other authors, as 
summarized by Greenblatt et al. (10). In a previous study (11), Wagner et aL 
reported a systemic availability of 80% of the dose, based upon AUC 
0-96 hr, when 0.5 mg doses of digoxin were administered orally in the same 
type of solution as used in the study being reported herein. However, 
reevaluation of those data by Wagner and Ayres (5) and estimation of AUC 
0-oo indicated that the digoxin was completely absorbed (100%) after the 
oral solution rather than the originally reported 80%. 
One possible variable that could have affected the results in our study 
was posture. In the present study, the subjects were supine (horizontal) 
during most of the day when digoxin was administered, whereas in previous 
digoxin bioavailability studies performed by the senior author, subjects were 
always ambulatory (upright). Culbertson et at. (12) reported that estimated 
hepatic blood flow, as measured by intravenous bromsulfalein, decreased in 
normotensive subjects by 37.5% (from a mean of 1.71 liters/rain/1.73 m 2 
to 1.07 liters/rain/1.73 m 2) when subjects changed from the horizontal to 
the upright body position. Smith and Shimizo (13) reported that lithium 
renal clearance was 30% lower while standing than while reclining; also, 
clearances of creatinine, sodium, and potassium were all lower while stand- 
ing than while reclining. The only other digoxin bioavailabitity study that 
was performed when the normal volunteers were supine that we could find in 
the literature was that of Huffman and Azarnoff (14). Their data differed 
from most subsequent digoxin bioavailability data in that following 
intravenous and oral administration of 0.5 mg doses, only 57 and 53% of the 
doses, respectively, were excreted in the urine in 10 days. Thus although 
these percentages are similar, the percentage of the dose excreted was low 
relative to most other reported data. It is feasible that in the supine posture 
and oral administration, a greater portion of the digoxin dose gets metabol- 
ized in the liver as a result of higher effective liver blood flow, and, also, that 
less gets absorbed as a result of less physical activity; hence, less'motility 
and/or contact of part of the digoxin solution in the lumen of the gastroin- 
testinal tract with the absorbing membrane. One final comparison is of 
interest. In our study, the overall mean renal clearance of digoxin was 
194 ml/min (average of the four values in row 6 of Table IV), which agrees 
very well with the average of 191 ml/min reported by Keller et al. (15). 
160 Wagner, Popat, Das, Sakmar, and Movahhed 
It is unlikely that the results we report were caused by the nonspecificity 
of the digoxin radioimmunoassay. Seventeen randomly selected plasma 
samples from this study were assayed not only by the direct RIA (nonspecific 
method), but also by a method in which digoxin was separated from its 
metabolites by HPLC, the digoxin fraction collected at the end of the HPLC 
column, then the digoxin assayed by RIA (specific method). The mean 
nonspecific assay, 1.92 ng/ml, did not differ significantly from the mean 
specific assay, 1.79 ng/ml (paired t = 1.21, p > 0.10). Similarly, 34 randomly 
selected 24-hr urine collections from days 1 through 4 were assayed by the 
two methods. The mean nonspecific assay, 15.5 ng/ml, did not differ 
significantly from the mean specific assay, 15.4 ng/ml (paired t = 0.12, 
p > 0.25). Details of our specific digoxin assay will be published elsewhere. 
Relatively low concentrations of digoxin metabolites in both plasma or 
serum and urine, capable of cross-reacting in the radioimmunoassay, have 
been reported for subjects and patients with normal renal function recently 
by others (16,17). Gault et al. (16) administered 150 ixCi3H-digoxin-12oz 
orally to six subjects with normal renal function and collected urine for 5 
days. Digoxin and its metabolites were separated using diethylaminoethyl 
Sephadex LH-20 column chromatography, and the amount of each was 
measured. Mean cumulative percentages of the ingested radioactivity 
excreted in the 5 days in the urine were 54.5% digoxin, 0.5% bis-digitox- 
oside, 0.19% monodigitoxoside, 0.03% digoxigenin, and 0.03% dihy- 
drodigoxin. Gibson and Nelson (17) administered digoxin to nine subjects 
with various degrees of renal function but not requiring dialysis, collected 
plasma samples, separated digoxin from its metabolites by high performance 
liquid chromatography, then collected the fraction corresponding to digoxin 
and measured the digoxin by radioimmunoassay. They also assayed the sera 
using the RIA directly. The ratio of HPLC digoxin/direct RIA digoxin 
averaged 1.06 with a range of 0.94 to 1.24. Thus the percentages of digoxin 
metabolites, relative to digoxin itself in both plasma and urine of volunteers 
with normal renal function, are very small. Reports of metabolites of digoxin 
in patients with impaired renal function and/or cardiac disease are not 
pertinent to this report involving normal volunteers. 
There is another point of interest in the urinary data reported by Gault 
et al. (16). Their semilogarithmic plots of urinary excretion rates versus time 
show that each metabolite has a markedly different elimination rate constant 
and halflife than that of digoxin. If urinary excretion rate constants of the 
metabolites are greater than their formation rate constants, one would 
expect at least the corresponding bis-glycoside and dihydrodigoxin to have 
the same elimination halflives as digoxin as a result of the precursor-product 
relationship in a catenary chain with parallel paths. The fact that they don't 
suggests that all of the metabolites may have been formed on the "first pass" 
through the liver following oral administration. 
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A similar finding, as we report here for digoxin in man, was reported by 
Frey et al. for prednisolone in the dog (18). Using the total clearance 
estimated from bolus iv data resulted in overestimation of the steady state 
concentration following infusions. Thus the total clearance for infusions was 
greater than the total clearance obtained from bolus iv data. 
It should be noted that the mean areas under the plasma concentration- 
time curves from 0 to 8 hr after bolus intravenous and from the start of the 
infusions to 8 hr after the infusions ceased for the 1 and 3 hr infusions in our 
study did not differ significantly (F = 2.83, 0.25 >p  > 0o10) when analyzed 
by analysis of variance for crossover design. However, the mean dose 
corrected areas per 0.5 mg of digoxin (AUC 0-96 hr) and mean dose 
corrected total areas per 0.5 mg of digoxin (AUCO-~) were highly 
significantly different in our study (see Table V, rows 1 and 3). These data 
support the conclusions and simulations done by Wagner and Ayres (5), and 
indicate that much of the plasma or serum digoxin concentration-time data 
in the literature is of little use, since samples were not taken for a sufficiently 
long period of time, and no extrapolation to infinite time was possible. These 
data also indicate that the suggested time of blood sampling of 6 hr recom- 
mended by the Food and Drug Administration is a poor choice. 
Since in our study, both the total clearance and the nonrenal clearance 
of digoxin changed significantly with the method of intravenous adminis- 
tration, there are no suitable equations to estimate digoxin bioavailability. 
Also, since in our study an infinitely dilutable aqueous solution of digoxin 
without digoxin precipitation (as can occur with the injectable form or as 
alcohol elixir) gave very low amounts in the urine and relatively low areas, 
this brings up many questions about the assessment of digoxin bioavailabil- 
ity as it has been done in the past. 
A P P E N D I X  
Methods  of Estimating Areas Under  Plasma Concentrat lon-Time Curves 
In general, the area under the concentration-time curve, (AUC)i, to 
time ti was estimated by means of Eq. (A1): 
(AUC)i = ~ou dt + f]C dt (A1) 
where tp is the time of the observed peak concentration (10 rain or 0.167 hr 
for bolus iv, 1 hr for the 1 hr infusion, 3 hr for the 3 hr infusion, and 0.75, 
0.75, 1, 0.75, 0.5, and 0.75 hr for subjects 1 through 6, respectively, after 
oral administration). The first integral on the righthand side of Eq. (A1) was 
estimated by trapezoidai rule, while the second integral on the righthand 
side was estimated by means of the logarithmic trapezoidal rule. For bolus iv 
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administration, the area estimated was the most conservative one, since the 
first integral was obtained by assuming zero concentration at zero time and, 
hence, the first integral on the righthand side of Eq. (A1) was estimated 
using Eq. (A2): 
ou C dt = 89 ) (A2) 
where C0.167 was the observed plasma concentration at 0.167 hr. When 
t~ = T = 96 hr, then (AUC)g = AUC 0-T; the mean areas per 0.5 mg dose of 
digoxin obtained in this manner are shown in row 1 of Table III. Total areas, 
AUC 0-~,  were estimated by three different methods. 
Method 1 
This utilized the method of Wagner and Ayres (5), and is based on Eq. 
(A3), initially published by Wagner et al. (19): 
(AUC)I = AUC 0-oo- [1 1 
_ _  7-/3A, ] [(AUC),+I - (AUC)~] (A3) 
In applying this method to concentrations measured following bolus iv and 
oral administrations, the (AUC)i's were AUC 0-24, AUC 0-48, AUC 0- 
72, and AUC0-96;  for the 1 hr infusion data, they were AUC0-25,  
AUC 0-49, AUC 0-73, and AUC 0-97; and for the 3 hr infusion data, they 
were AUC 0-27, AUC 0-51, AUC 0-75, and AUC 0-99. The method of 
least squares was applied to the four areas for a given subject after a given 
treatment using the (AUC)i's as ordinate (y) values and the differences 
(AUC)i+I - (AUC)I as the abscissa (x) values. The intercept was the desired 
total area, AUC 0-~,  and from the slope the elimination rate constant,/3, 
was obtained with At = 24 hr. 
Method 2 
This was based on the classical method shown in Eq. (A4): 
AUC 0-oo = AUC 0-96 + C96//3 (A4) 
Here AUC 0-96 was obtained using Eq. (A1) above. The second term on 
the righthand side of Eq. (A4) is an estimate of the area from 96 hr to 
infinity. In this method, the elimination rate constant was estimated by 
applying the method of least squares to plasma concentrations, C, measured 
at the last four sampling times using Eq. (A5), 
In C = In B -/3t (A5) 
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then obtaining the estimated concentration at 96 hr, symbolized by C'96 
using Eq. (A6); 
C96 = e[lnB-96t3] ( A 6 )  
Method 3 
This method was based on fitting a polyexponential equation to the 
concentration-time data, then integrating the equation to obtain the esti- 
mated total area. The number of exponential terms needed to obtain an 
excellent fit was either 3 or 4. For bolus iv, all data of each set (except a 0,0 
point) were fitted to Eq. (A7), 
C = Y Ci e-~" (A7) 
i=1 
then the area from 0.167 hr to infinity was obtained using Eq. (A8): 
<3O 
Io C dt = Ci -0.167Ai (A8) 
.167 ,~-'~- e 
To that area was added the area from 0,0 to 0.167 hr obtained with Eq. (A2) 
provide the desired AUC 0-oe. Oral data were fitted with Eq. (A7), then 
integrated from 0 to oo as shown by Eq. (A9): 
fo Cdt  = Ci/Ai (A9) 
Postinfusion data were fitted to a polyexponential equation and that portion 
integrated to provide the area from the end of the infusion to infinite time. 
To this was added the area from zero to the end of the infusion, which was 
estimated by trapezoidal rule. 
Method of Estimating the Amount of Digoxin Excreted in the Urine in 
Infinite Time 
The method of least squares was applied using the amounts excreted 
from days 2 through 6 or 3 through 6 (Ae)i and a similar equation to Eq. 
(A3), except (Ae)i replaced (AUC)i, Ae ~ replaced AUC 0-ce, and (Ae)i+l 
replaced (AUC)i+I. 
Methods of Estimation of Other Pharmacokinetic Parameters 
Total clearance, Clt, was estimated with Eq. (A10): 
Cl, = D/(AUC 0-oe) (AIO) 
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Renal clearance, Clr, was estimated with Eq. (Al l ) :  
Clr = A e ~ /  ( A U C  0-~)  (Al l )  
Nonrenal clearance, Clnr, was estimated with Eq. (A12): 
Cl,,r = CI t -  Ctr (A12) 
Elimination rate constants,/3, were estimated three different ways: (a) 
by use of Eq. (A3); (b) by use of 2 or 3 through 6 day cumulative urinary 
excretion and a modification of Eq. (A3), where (Ae)~ and (Ae)~+l replace 
(AUC)~ and (AUC)~+I; and (c) by use of Eq. (A5) with the concentrations 
corresponding to the last four sampling times. 
Elimination halflife, t89 was obtained with Eq. (A13): 
t~ = 0.693//3 (A13) 
Volume of distribution, V m was obtained using Eq. (A14): 
Vt~ = Cl,/ /3 (A14) 
Apparent systemic availability was calculated by three methods as follows. 
Method A 
This method assumes constant Cl,, but variable Cl~ and is estimated by 
means of equation (A15) as reported formerly (19): 
Ds(AUC 0-oO)x [CI'~ - CI~](AUC 0-oo)x 
Fx/Fs  - (A15) 
Dx (AUC O-oo)s Dx  
where x refers to other treatment (1 hr infusion, 3 hr infusion, or oral) and s 
refers to bolus iv. Equations reported by Kwan and Till (20) and Oie and 
Jung (21) are exactly equivalent to Eq. (A15). 
Method B 
This method assumes a proportional change in Cln~ with change in Cl~ 
and was estimated by Eq. (A16): 
(ae  ~ )x /Dx  
Fx/Fs = (A16) 
(Ae~)s /Ds  
Method C 
This method assumes constant total clearance and was estimated by Eq. 
(A17): 
(AUC)x Ds 
Fx/Fs  = (A17) 
(AUC)s Dx 
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A C K N O W L E D G M E N T  
W e  t h a n k  t h e  n u r s e s  o f  t h e  C l in i ca l  R e s e a r c h  C e n t e r  fo r  t h e i r  assis~ 
t ance .  
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